Enliven therapeutics reports fourth quarter and full year 2024 financial results and provides a business update

Updated phase 1 data for elvn-001 expected mid-2025 as positive enrollment momentum continues expected monotherapy and combination data from the elvn-002 phase 1 trials in second half of 2025 strong balance sheet with $313 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into mid-2027 boulder, colo. , mar. 13, 2025 /prnewswire/ -- enliven therapeutics, inc. (enliven or the company) (nasdaq: elvn), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the fourth quarter and full year ended december 31, 2024, and provided a business update, including highlights of pipeline progress.
ELVN Ratings Summary
ELVN Quant Ranking